The Financial Times profiles the Drugs for Neglected Diseases Initiative (DNDi), which is recognizing its 10th anniversary this month. “DNDi has delivered six treatments for neglected diseases and has 12 ‘new chemical entities’ under development,” the newspaper writes, adding, “At €183 million [$252 million] spent to date, that translates into a modest price tag for each successfully launched medicine compared to the costs for drugs launched by drug companies” (Jack, 12/10).